ATAI Life Sciences NV
NASDAQ:ATAI
ATAI Life Sciences NV
NASDAQ:ATAI
Price:
1.39 USD
-6.08%
Market Closed
Updated:
Jun 9, 2024
ATAI Life Sciences NV
Income from Continuing Operations
|
ATAI Life Sciences NV
Income from Continuing Operations Peer Comparison
Comparables:
BAYN
MRK
93M1
DMP
PSG
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Income from Continuing Operations
-$40.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Income from Continuing Operations
-€3.1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Income from Continuing Operations
€2.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
23%
|
CAGR 10-Years
8%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Income from Continuing Operations
€29.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Income from Continuing Operations
€54.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Income from Continuing Operations
€16.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
See Also
What is ATAI Life Sciences NV's Income from Continuing Operations?
Income from Continuing Operations
-40.3m
USD
-40.3m
USD
Based on the financial report for Dec 31, 2023, ATAI Life Sciences NV's Income from Continuing Operations amounts to -40.3m USD.
What is ATAI Life Sciences NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
27%
27%
Over the last year, the Income from Continuing Operations growth was 71%. The average annual Income from Continuing Operations growth rates for ATAI Life Sciences NV have been 27% over the past three years .
You don't have any saved screeners yet
